RNS Number : 6424H
BSF Enterprise PLC
20 March 2024

20 March 2024

BSF Enterprise PLC

("BSF" or the "Company")

Result of Annual General Meeting

BSF Enterprise (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based tissue engineering company 3D Bio-Tissues Ltd (3DBT) and corneal tissue replacement company Kerato Ltd, is pleased to announce that at the Company's Annual General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows:

Resolution		Poll Results				
		For	Against	Withheld	Discretionary	Total
1	Shares	52,426,227	-	-	-	52,426,227
	%	100.00%	-	-	-	100%
2	Shares	52,421,227	5,000	-	-	52,426,227
	%	99.99%	0.01%	-	-	100%
3	Shares	52,421,227	5,000	-	-	52,426,227
	%	99.99%	0.01%	-	-	100%
4	Shares	52,426,227	-	-	-	52,426,227
	%	100.00%	-		-	100%
5	Shares	46,646,377	-	5,779,850	-	52,426,227
	%	88.98%	-	11.02%	-	100%
6	Shares	52,426,227	-	-	-	52,426,227
	%	100.00%	-	-	-	100%
7	Shares	52,402,826	23,401	-	-	52,426,227
	%	99.96%	0.04%	-	-	100%
8	Shares	52,421,227	-	5,000	-	52,426,227
	%	99.99%	-	0.01%		100%
9	Shares	52,397,826	23,401	5,000	-	52,426,227
	%	99.95%	0.04%	0.01%	-	100%

About BSF Enterprise PLC:

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cellbased tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas for testing to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality leather from its laboratory in Newcastle, transforming the leather industry towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to develop a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC	Via SEC Newgate below
Geoff Baker - Executive Director	
Che Connon - CEO & Director	
Shard Capital (Broker)	
Damon Heath	0207 186 9000
Isabella Pierre	0207 186 9927
SEC Newgate (Financial Communications)	
Bob Huxford	020 3757 6882
Elisabeth Cowell	BSF@secnewgate.co.uk

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGURVURSVUOUAR